Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

GSK Says It Acted ‘Appropriately’ In Response to Paxil Class-Action

By Pharmaceutical Processing | December 7, 2012

VANCOUVER – GlaxoSmithKline says it conducted its clinical trial program for the anti-depressant drug Paxil appropriately in marketing the medicine for use by women of childbearing age.

The statement comes after a B.C. Supreme Court judge certified a class-action lawsuit launched by a British Columbia mother whose daughter was born with a hole in her heart.

Lawyers allege the drug caused birth defects when taken during pregnancy, and say the company didn’t properly warn doctors about the risks.

In a statement, spokeswoman Michelle Smolenaars Hunter says the company acted appropriately in its clinical trials, marketing, safety monitoring and updated pregnancy information as new information became available.

Faith Gibson’s daughter Meah Bartram was born just two weeks before the company warned doctors that taking the drug during pregnancy could increase the chance of cardiovascular defects.

One of her lawyers, David Klein, argues the company ought to have know the risks before then, and is pointing to small-scale studies and studies on similar products that were already available to the scientific community.

But Smolenaars Hunter says the company acted responsibly.

“The company properly shared documentation and submitted results from studies on Paxil to regulators,” she said in an email on Thursday, “and communicated important safety information to regulatory agencies, the scientific community and health-care professionals.”

The company says it is currently evaluating its options with regard to the class certification.

It applies to women who took the drug in Canada.

No allegations have been proven in court.

Klein said about a dozen women have come forward so far. A notice of the suit will soon be distributed across the country. A trial isn’t expected for a couple years.

 

 

Related Articles Read More >

FDA logo
Ultra Supplement announces recall for undeclared tadalafil
analyzing medical sample
Expert answers to nitrosamine impurity questions
Cardinal Health
Cardinal Health announces $124M settlement of investors’ opioid suit
FDA logo
FDA warns four companies over selling honey tainted with prescription drugs

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards